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Metallothionein (MT) was reported to be a potential negative regulator of apoptosis, and various reports have
suggested that it may play roles in carcinogenesis and drug resistance, in at least a portion of cancer cells. The
author summarizes the current understanding of the molecular functions of MT for tumor cell growth and drug
resistance. These activities are regulated through intracellular metal ion modulation and free radical scavenging.
Compared with analyses of solid tumors, few studies have analyzed the roles of MT in hematological malignancies.
This review mainly describes the functions of MT in hematopoietic cells. Furthermore, through expression analyses
of leukemias and lymphomas, the roles of MT in the biology of these diseases are particularly focused upon.
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Metallothionein (MT) was first isolated by Margoshes
and Vallee [1] as a cadmium-binding low-molecular
weight protein from the horse kidney. MT proteins com-
prise a group of low-molecular weight cysteine-rich
intracellular proteins [2]. Structural studies have shown
that these unusual proteins with 61 amino acids can
bind to both essential metals (zinc and copper) and toxic
metals (cadmium and mercury). MTs are characterized
by their low molecular weight, high cysteine content,
lack of aromatic amino acid residues and presence of 7–12
metal atoms per molecule [3,4]. Owing to their rich thiol
content, MTs bind a number of trace metals including
zinc, cadmium, mercury, platinum and silver, and also
protect cells and tissues against heavy metal toxicity.
The level of metal ions, affects on normal hematopoietic
cell proliferation and differentiation. For example, zinc
deficiency in mice result in the overall decline in the ab-
solute number of lymphocytes in concordance with in-
crement of the granulocytes and monocytes [5]. Since
MT binds to metal ions, MTs may play a role in the
hematopoietic cell proliferation/differentiation.
Two major isoforms of MT, designated MT-I and MT-II,
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reproduction in any medium, provided the orhave been identified in mammals, and are found in all
types of tissues [6,7]. Moreover, two other members,
designated MT-III and MT-IV, are expressed in limited
tissues as minor isoforms [8,9]. In humans, the MT genes
are located on chromosome 16 q13 in a cluster and may
involve at least 10 identified functional genes [2].
Although the MT-II, MT-III and MT-IV proteins are
encoded by a single gene, the MT-I protein comprises
many subtypes encoded by a set of MT-I genes. The
known functional MT-I and MT-II isoforms are MT-IA,
-IB, -IE, -1F, -IG, -IH, -IX and –IIA [2]. Differential regu-
lation in response to heavy metals has been reported for
some members of MT gene family. For example, quan-
titative analysis of MT-IIA, MT-IF and MT-IG gene
expression in HepG2 cell line has indicated that these
genes are differentially regulated in terms of both the
rate and extent of transcript accumulation [10]. The
MT-IIA and MT-IG mRNA levels are approximately 20-
and 4-fold higher than that of MT-IF mRNA, respect-
ively. The expression of the MT-IIA and MT-IA genes
have been detected in all cell types studied [11,12],
while other MT genes such as MT-IB and MT-IE are
expressed in a cell-type specific manner [13,14]. Differ-
ent cells express different MT isoforms with varying
levels of expression perhaps as a result of the different
function of each isoform. Therefore, the fact that multiple
MT isoforms exist, and the great variety of substances
and agents that acts as inducers, complicates the search
for the biological role of each MT isoform.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Takahashi Journal of Hematology & Oncology 2012, 5:41 Page 2 of 8
http://www.jhoonline.org/content/5/1/41To date, there are no studies for mice with single MT-
I or -II deletion, therefore, the functional difference be-
tween MT-I and II remain obscure. However, several
groups have reported phenotype of double MT-I and -II
gene knockout mice [15,16]. From these studies, al-
though some differences in phenotype and metabolic
responses may exist, susceptibility to heavy metal tox-
icity, response to inflammation and zinc homeostasis is
common features of the phenotypes of these double
knockout mice.
Transgenic mice with multiple MT-I genes, have 10–20
fold greater MT protein levels in the pancreas, liver and
stomach, and 2–6 fold greater MT levels in a number of
other organs including kidney, spleen and heart [17].
They have 50% more zinc in liver and 300% more in the
pancreas [17]. Pancreatic MT of these mice has been
found to be a very sensitive indicator of zinc status [18].
A number of studies have shown that increased MT
expression is closely associated with tumor grade and
proliferative activity in solid tumors [2]. Another study
reported increased levels of MT-I and MT-II mRNA and
protein expression in various human cancers, such as
breast, kidney, lung, nasopharyngeal, ovarian, prostate,
salivary gland, testicular, urinary bladder, cervical and
endometrial cancers, as well as skin carcinoma and mel-
anoma [19]. However, MT-I and MT-II are downregu-
lated in other types of tumors, e.g. hepatocellular,
gastric, colorectal, central nervous system and thyroid
cancers. Several lines of evidence suggest roles for MTs
in cancer development, treatment resistance and poor
prognosis [20,21]. Studies of the mutations of MT using
clinical specimens that could influence the expression of
this gene are scarce. Tai et al. [22] demonstrated nonsi-
lent mutations in MT-IH gene in several breast cancer
cell lines, however, there are no differences of MT-IH
expression in tumors and normal tissues.
Several reports have suggested that MTs are also
involved in the pathogenesis of hematological malignan-
cies [23-29]. Furthermore, the author’s group recently
demonstrated that MT-I expression is directly regulated
by the hematopoietic transcription factor PU.1 [26].
Overexpression of MT-I was significantly correlated with
downregulation of PU.1, which is frequently observed in
various hematological malignancies such as acute mye-
loid leukemia (AML) [26]. However, compared with
other tumors, studies of MT in hematological malig-
nancies are relatively scarce. The aim of this review is
to describe the roles of MT in hematological malig-
nancies. Furthermore, this review summarizes the
current understanding of the molecular functions of MT.
MT in cell growth
MT can be activated by a variety of stimuli, including
metal ions, cytokines and growth factors [2]. In addition,MT was reported to be induced by radiation [30]. In
fact, the synthesis of MT was shown to be increased by
several-fold during oxidative stress [31] to protect the
cells against cytotoxicity [32] and DNA damage [33].
The stimuli that induce MT and the downstream effects
of MT overexpression are summarized in Figure 1. MT
expression in tumor tissues is mainly correlated with
the proliferative capacity of tumor cells [34]. However,
there are few exceptional cases like downregulation of
MT-I, -II in hepatocellular carcinoma [35], and also
reduced level of intracellular zinc result in the increment
of granulocyte, but the decreased number of lymphocytes
[5].
MT regulation during cell cycle progression has been
demonstrated in normally cycling cells. Maximal nu-
clear accretion of MT by two- to three-fold the basal
level was found to coincide with the S and G2 phases,
while high cytoplasmic expression occurred during late
G1 phase and G1/S transition and basal amounts were
found in G0 phase [36,37]. The MT-I location on the
antiapoptotic function was studied by Levadoux-Martin
et al. [38]. They revealed that the perinuclear
localization of MT-I mRNA is important for the func-
tion of MT in a protective role against DNA damage
and apoptosis induced by external stress. In another
study, four-fold increases in MT-II were found in prolif-
erating liver cells compared with those in growth arrest,
and there was evidence for translational control as well
as a slower rate of MT-II degradation in proliferating
cells [39].
MT can facilitate tumor cell growth or drug resist-
ance by two potential mechanisms (Figure 1). First,
MT may play an essential role in development and
growth through the maintenance of zinc metabolism.
The translocation of MT into the nucleus during the
proliferative phase (G1–S) of the cell cycle in human
tumors also supports a zinc donor role for MT during
tumor growth [40]. The nuclear accumulation of MT
may be important for supplying zinc or other metals
to target molecules, including enzymes, zinc-finger
transcription factors and tumor suppressor gene pro-
ducts such as p53 [6,41-45]. Meplan et al. [43]
demonstrated that zinc incorporation is required for
the stablization of wild-type recombinant p53 in a
form capable of binding speficically to DNA. They also
showed that human recombinant thionein, the metal-
free form of MT, reported to remove zinc from zinc
finger transcription factors Sp1 thereby abrogating
their transcriptional activity [46,47], inhibited binding
of p53 to a specific consensus sequence in vitro. Sup-
plementation of thionein with equimolar amounts of
zinc prior to incubation with p53 abrogated this effect.
Co-transfection experiment using p53-dependent re-
porter gene with p53 and MT expression vectors
MT
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Figure 1 Schematic presentation of the stimuli that induce MT, and the downstream effects of MT overexpression. Two potential
mechanisms that facilitate tumor cell growth or drug resistance are illustrated as downstream effects of MT overexpression. The indicated
numbers are the references cited in this review.
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compared to p53, MT exerts an inhibitory effect, by
an average of 50%, consistent with a metal chelator ef-
fect of MT. However, when expressed at lower levels,
MT may catalyze metal-transfer reactions regulating
the folding of the DNA-binding domain of p53, thus
enhancing its activity of p53 to approximately 300%
[43]. Second, MT can protect the cells against radi-
ation and chemotherapeutic agents by virtue of its free
radical scavenging property [48,49]. The antioxidant
properties of MT contribute to its antiapoptotic func-
tion [50]. In particular, MT synthesis is induced follow-
ing treatment with cadmium, an environmental
pollutant that causes oxidative stress, DNA damage
and apoptosis [51,52]. Nuclear factor (NF)-κB is a
transcription factor that also plays a role in the antia-
poptotic function of MT. NF-κB activity is regulated
by the intracellular redox status, and reactive oxygen
species may be involved in the NF-κB activation cas-
cade. Abdel-Mageed et al. [53] revealed that, in breast
carcinoma MCF-7 cells, MT caused transactivation of
NF-κB through a direct interaction. They suggested a
potential role for NF-κB in mediating the antiapoptotic
effects of MT. However, Sakurai et al. [54] demon-
strated that the DNA-binding activity of NF-κB is
impaired in MT null embryonic cell lines. Although
the role of MT for NF-κB activation remains contro-
versial, these findings indicate that MT expression maybe necessary for the growth and survival of tumor
cells.
MT in drug resistance
The protective roles of MT against oxidative stress and
metal toxicity suggest that MT may also have a func-
tional role in drug resistance. Using several cell lines
(PLC/PRF/5, H460 and HepG2), Shimoda et al. [55]
revealed that induced MT levels were negatively corre-
lated with sensitivity to etoposide-induced apoptosis,
suggesting that MT is a potential negative regulator of
apoptosis. Kondo et al. [56] investigated embryonic
fibroblast cells from transgenic mice with targeted dis-
ruptions of the MT-I and MT-II genes (MT−/−), and
found that MT−/− cells showed enhanced sensitivity to a
2-h exposure to anticancer drugs, including cisplatin,
melphalan, bleomycin and cytarabine, compared with
wild-type cells (MT+/+). In addition, both human pri-
mary hepatocellular carcinoma and metastatic carcin-
oma had low MT levels and higher numbers of
apoptotic cells compared with the normal liver [57,58].
However, the role of MT in the development of che-
moresistance in the clinical setting is still controversial.
Studies in human tumors, such as ovarian, testicular and
colon tumors, appear to suggest that overexpression of
MT may have protective effects against antineoplastic
agents [59,60], whereas other reports do not support this
perception [61,62].
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Mouse embryonic stem (ES) cells, remain pluripotent
in vitro when grown in the presence of leukemia inhibi-
tory factor (LIF). However, it was shown that apoptosis
but not morphological cell differentiation, induced by
withdrawal of LIF, was blocked by inhibition of p38 ac-
tivity through PD169316 [63]. Duval et al. [64] com-
pared the gene expression profiles of embryonic stem
(ES) cell-derived differentiated cells by LIF withdrawal,
in the presence or absence of PD169316. They showed
that overexpression of MT-I prevented apoptosis of early
differentiated cells [64]. These observations suggest that
MT-I plays positive roles in the growth and anti-
apoptosis of ES cells.
Maghdooni Bagheri et al. [65] examined the expres-
sion levels of MT among the hematopoietic precursor
cell lines K562, DAMI, MEG-01 and EFL-153. They
revealed that the more mature K562, DAMI and MEG-
01 cells had higher MT levels than the immature ELF-
153 cells. Treatment of K562 cells with phorbol ester
leads to loss of their erythroid properties and to acquisi-
tion of several megakaryoblastoid charachteristics [66].
They further found that phorbol ester induction of K562
cells resulted in an increase in MT transcription and
biosynthesis [65]. Consistently, the same group recently
reported that in human cord blood cells, MT is more
highly expressed in mature CD34– cells than in imma-
ture CD34+ cells [67].
In the megakaryocytic lineage, it was recently reported
that overexpression of MT-IIA in megakaryocytic DAMI
cells caused increases in the cell size, intracellular granu-
lation and levels of megakaryocytic-specific CD41 and
CD42 with arrest of cell proliferation, suggesting a posi-
tive role for MT in megakaryocytic differentiation [68].Table 1 Roles of MT in hematopoietic cells
Lineage Cells Role
Undetermined ES-derived differentiated cells Overexpression of MT
in ES derived differen
Undetermined human cord blood cells MT is more highly ex
Megakaryocyte Megakaryocytic DAMI cells Overexpression of MT




K562, DAMI, MEG-01, ELF-153 The more mature K5
MT isogenes, except
Phorbol ester induce
Erythroid K562 cells EPO- or sodium buty
formation was inhibi
containing human M




is enhanced, with pre
T lymphoid T cell line CCRF-CEM Inhibition of hMTs syIn the erythroid lineage, it has been reported that under
conditions of induced erythropoiesis or anemia, the induc-
tion of MT in the rat bone marrow is enhanced, with pre-
dominant accumulation in erythroblasts [69]. However, in
non-anemic rats, the induction of MT in bone marrow
requires prior treatment with erythropoietin (EPO) [69].
The detection of an appreciable quantity of MT proteins in
mature erythrocytes suggests that the source of MT in red
blood cells may be induction of marrow erythroid precur-
sor cells by EPO. Abdel-Mageed et al. [70] reported that
EPO induced a three-fold increase in MT transcripts in
K562 cells. MT induction was associated with EPO-
induced cellular proliferation. However, EPO- or sodium
butyrate-induced differentiation was inhibited in K562 cells
stably transfected with an expression vector containing the
human MT-IIA gene [70]. These findings may indicate a
positive role for MT in the proliferation of erythroid cells,
as well as a negative role for erythroid differentiation. Con-
sidering the positive role of MT for differentiation in the
megakaryocytic lineage [68,70] and the negative role of
MT for erythroid differentiation [68,70], the roles of MT
toward differentiation may differ in different lineages.
Tsangaris et al. [71] examined the role of MTs in the
apoptotic process by inhibiting their expression in the
immature T cell line CCRF-CEM using antisense
sequence-specific phosphorothioate oligodeoxynucleo-
tides (ODNs). They found that the inhibition of MT syn-
thesis by the ODNs stimulated the apoptotic process, as
demonstrated by TUNEL assays. Collectively, the known
experimental results for MT functions in hematopoietic
cells are summarized in Table 1.
In the myeloid lineage, no studies analyzing MT func-
tions have been published to date. Since MT possesses
potent antioxidant functions and the generation ofRef.
-I gene prevents LIF withdrawal induced apoptosis
tiated cells
[64]
pressed in mature CD34– cells than in immature CD34+ cells [67]
-IIA resulted in the increase of cell size, intracellular granulation
megakaryocytic specific CD41 and CD42 and arresting in
[68]
62, DAMI, and MEG-01 cell lines exhibited transcription of all
MT-III and MT-IV.
[65]
s increased MT transcription and biosynthesis.
rate-induced differentiation as monitored by hemoglobin
ted in K562 cells stably transfected with an expression vector
T-IIA gene.
[70]
is or anemia in rats, the induction of MT in the bone marrow
dominant accumulation in erythroblasts
[69]
nthesis by ODNs stimulated the apoptotic process [71]
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neutrophils for antibacterial activity, MT may also play a
role in this lineage. Further clarification of the molecular
functions of MT in this lineage may lead to better
understanding of hematopoiesis.
Expression analyses of MT in leukemia
Genetic mutations as well as overexpression of a certain
gene play important roles in the pathogenesis of
hematological malignancies [72]. In this context, altera-
tions in the expression of MT genes have been reported
in hematological malignancies (Table 2). Sauerbrey et al.
[73] examined the expression of MT in initial (n = 92)
and relapsed (n = 27) childhood acute lymphoid
leukemia (ALL). Although there was a tendency for
patients with initial ALL and MT expression to have a
lower probability of disease-free survival than patients
without MT expression, no differences in the percen-
tages of MT positivity and staining intensity in children
with either initial or relapsed ALL were noted [73]. They
concluded that MT expression was independent of clin-
ical prognostic factors such as age, sex, immunological
subtype and initial blast cell count in patients with initial
or relapsed ALL [73].
On the contrary, Tsangaris et al. [23] demonstrated
that expression of MT was correlated with chemother-
apy resistance. They examined MT expression in 47 chil-
dren with ALL, and found that 18 cases were positive





Results of the analysis
ALL 119 (initial: n = 92,
relapsed: n = 27)
Tendency in initial ALL with MT e
However, no differences concerni
children with either initial or relap
in the clinical drug resistance of c
ALL 47 After chemotherapy, MT positive
treatment and apoptotic action c
maximal effect on the first day of
ALL 60 From microarray CGH analysis, BA
between ALL patients at diagnosi
AML 19 The expression of resistance-relate
Patients who developed a relapse
more often than patients who rem
resistance-related proteins in child
AML 43 mRNA expressions of the MT-IA, G
(MT-IG: R =−0.50, p< 0.001; MT-IA
HL 35 MT is differentially expressed in su
immunostained cells is significant
(p< 0.001), and also, the number
NLPHL and LRCHL (p< 0.005).
DLBCL 115 MT labeling of more than 20% lym
survival, independent of age, stag
MPD OMF (n = 9),
CML (n = 11)
Increased GST-pi and MT expressi
patients were higher than in CMLcurve of these 18 cases showed that the maximal effect
occurred on the second day of treatment, and the apop-
totic action was completed on the tenth day. In contrast,
the mean apoptosis curve of the 29 MT-negative cases
revealed higher sensitivity to the treatment, with the
maximal apoptotic effect on the first day and completion
of the apoptotic action on the sixth day. A recent study
by Usvasalo et al. [24] using microarray comparative
genomic hybridization (CGH) analyses revealed a prog-
nostic classifier in adolescent and young adult ALL
patients aged 10–25 years (n = 60). They demonstrated
that BCL2-antagonist/killer 1 (BAK1), cyclin-dependent
kinase inhibitor 2 C (CDKN2C), glutathione S-
transferase M 1 (GSTM1) and MT-IF formed a gene set
that differed between ALL patients at diagnosis who had
a risk of relapse and those who did not [24].
In AML, the expression of the resistance-related pro-
teins P-glycoprotein 170 (P-170), glutathione-S-transferase
pi (GST-Pi), topoisomerase-II (Topo II), thymidylate syn-
thase (TS) and MT was investigated in leukemic cells from
19 children with newly diagnosed AML [25]. Different
percentages of positivity for the examined proteins were
noted. MT was expressed in leukemic cells from 68% of
cases with newly diagnosed AML. Although the number
of patients was small, they concluded that patients who
developed relapse showed a poorer prognosis, and fre-
quently expressed more than two resistance-related pro-
teins, including MT, compared with patients who
remained in remission [25].Ref.
xpression, the lower probability of disease free survival.
ng MT percentage of positivity and intensity of staining in
sed ALL. MT expression is not an important prognostic factor
hildhood ALL.
[73]
cases (n = 18) showed maximal effect on the second day of
ompleted on the tenth day. MT negative cases showed
treatment and completed on the sixth day.
[23]
K, CDKN2C, GSTM1 and MT-IF as a gene set that differed
s who had a risk or relapse from those who did not.
[24]
d proteins P-170, GST-pi, Topo II, TS and MT was investigated.
expressed more than two resistance mechanisms significantly
ained remission (p = 0.005). The higher the number of
hood AML the poorer the prognosis of the patients.
[25]
and PU.1 genes were significantly, inversely correlated
: R =−0.58, p< 0.0005).
[26]
bclassified Hodgkin lymphoma. The number of MT-I, II
ly higher in MCHL relative to other subclassified HL groups
of these cells is significantly higher in NSHL relative to
[29]
phoma cells was associated with a significantly poorer 5-year
e, or international prognostic index.
[27]
on in the bone marrow of MPD patients. Levels of MT in OMF
.
[28]
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mRNA expressions of the MT-IA and MT-IG genes
were significantly inversely with the PU.1 gene corre-
lated in 43 primary acute AML specimens (MT-IG:
R =−0.50, p< 0.001; MT-IA: R =−0.58, p< 0.0005) [26].
Although the clinical outcomes of these patients were
not analyzed, we demonstrated that these genes were
directly regulated by the epigenetic activities of the
hematopoietic transcription factor PU.1. In 24 AML
cases, we previously reported that PU.1 expression was
inversely correlated with the tyrosine kinase receptor
FLT3 [74], and that strong expression of wild-type FLT3
was an unfavorable prognostic factor for overall survival
[75,76]. In addition, PU.1 expression was reported to be
a positive indicator for other hematological malignan-
cies, such as follicular lymphoma [77]. Although further
extensive analyses are required, it is possible that
increased MT-I expression represents a poor prognostic
marker for AML.Expression analyses of MT in lymphoma and
myeloproliferative disorders
In lymphoid malignancies, it has been indicated that the
MT-I and MT-II expression profiles may be useful for
discriminating between non-malignant and malignant
lymphoid neoplasms [27,78]. Hodgkin lymphoma (HL)
is a neoplastic disease consisting of two distinct entities:
nodular lymphocyte predominant HL (NLPHL) (5%) and
classical HL (CHL). CHL includes four histological sub-
types: nodular sclerosis HL (NSHL), mixed cellularity
HL (MCHL), lymphocyte-rich classical HL (LRCHL) and
lymphocyte depleted classical HL (LDHL) [79]. Frequen-
cies of these subtypes are, NSHL: 70%, MCHL: 20-25%,
LRCHL: 5%, LDHL : <1% [79]. Among these, LRCHL
has most favorable prognosis, less frequently associated
with B symptoms, bulky disease and mediastinal invol-
volvement compared with MCHL and NSHL, and al-
most half of the patients present in stage I. Penkowa
et al. [29] analyzed MT expression in the lymph nodes
of 34 patients with HL, comprising 15 patients with
NSHL, 11 patients with MCHL, five patients with
LRCHL and three patients with nodular lymphocyte-
predominant HL (NLPHL), and in controls. NSHL and
MCHL patients showed highly increased MT expression
throughout the lymph nodes. In contrast, MT expression
was barely increased in LRCHL patients relative to the
controls. NLPHL patients showed a distinct pattern of
heterogeneous MT expression, with increased MT in
nodular areas surrounded by MT-negative tissues.
Therefore, MT is differentially expressed in HL subclas-
sifications [29]. However, they also revealed that there
were no correlations between the clinical outcomes after
chemotherapy and the numbers of MT-I- and MT-II-positive cells in the lymph node parenchyma of the
patients with HL.
However, in diffuse large B-cell lymphomas (DLBCLs),
a significant inverse correlation between MT expression
and clinical outcome has been reported [27]. Through
mRNA profiling using Affymetrix assays, Poulsen et al.
[27] demonstrated that MT mRNA was upregulated in
15 of 48 DLBCLs, including 12 of 23 activated B-cell
type lesions and three of nine type-3 lesions. In contrast,
MT mRNA was low to undetectable in 16 germinal cen-
ter B-cell type DLBCLs. Only one of 15 patients with
upregulated MT mRNA achieved sustained remission,
suggesting that upregulated MT mRNA constitutes a
significant risk factor for treatment failure. Importantly,
they expanded their immunohistochemical analysis to
include an additional 67 DLBCLs (total, 115 DLBCLs),
and found that MT labeling of >20% of lymphoma cells
was associated with a significantly (p = 0.004) poorer
5-year survival, independent of age, stage or inter-
national prognostic index [27].
Wrobel et al. [28] analyzed the expressions of MT and
GST-Pi in bone marrow of patients with myeloprolifera-
tive disease (MPD). Although the number of patients
was small, comprising nine patients with osteomyelofi-
brosis (OMF) and 11 patients with chronic myelocytic
leukemia (CML), they revealed increased GST-Pi and
MT expression in the bone marrow of MPD patients.
The levels of MT expression in the OMF patients were
higher than those in the CML patients. These findings
suggest that MT expression may be correlated with bone
marrow fibrosis.Conclusions
Increasing evidence suggests that MT plays important
roles in oncogenesis through multiple functions. MT
functions, such as those in cell survival, cell growth,
drug resistance and differentiation have been precisely
studied in non-hematological diseases. To date, more
than 9,700 papers have been published about this
multifunctional protein related to tumorigenesis, toxi-
cology, cancer chemotherapy, inflammation, aging, and
so on. In this review, the author focused on MT func-
tions in hematopoietic cells, and the roles of MT in
these cells that have been described. Collectively, in
these cells, MT has been reported to play roles in
hematopoietic cell differentiation [64,65,67-69],
hematopoietic cell proliferation [64,70] and prevention
of apoptosis [71] (Table 1). It may also be related to
drug resistance in AML [25] and ALL [23], and is a
poor prognostic factor in DLBCL [27] (Table 2). Ex-
pansion of these directions toward hematological ma-
lignancies may further clarify the mechanisms
underlying hematological malignancies.
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